Devitronectin receptor antagonist compounds, kit, diagnostic or therapeutic metallopharmaceutical composition, ultrasound contrast agent composition, therapeutic radiopharmaceutical composition, diagnostic pharmaceutical composition, treatment method for rheumatoid arthritis, cancer and darthenosis in a patient, angiogenesis formation method therapy, cancer, new blood vessels, arteriosclerosis, darthenosis, ischemia and myocardial reperfusion injury in a patient

摘要

"RECEIVER ANTAGONIST COMPOUNDS DEVITRONECTINA, KIT, COMPOSITION METALOFARMACêUTICADE diagnostic or therapeutic, COMPOSITION DEAGENTE CONTRAST FOR ULTRASOUND, COMPOSIçãORADIOFARMACêUTICA therapeutic, diagnostic COMPOSIçãOFARMACêUTICA, METHOD Trick ARTHRITIS RHEUMATOID, OF CANCER AND DARESTENOSE in a patient, TRAINING METHOD DEIMAGEM OF THERAPEUTIC ANGIOGENESIS, CANCER, DENOVING BLOOD VESSELS, ARTERIOSCLEROSIS, DARESTENOSIS, ISCHEMIA AND INJURY BY REPERFUSION OF MYOCARDIAL IN A PATIENT ". The present invention describes new compounds of formula (Q) ~ d ~ - L ~ n ~ - C ~ h ~, useful for the diagnosis and treatment of cancer, methods for deforming tumors in a patient, and methods for treating cancer in a patient. The present invention also presents new compounds useful for monitoring the treatment of therapeutic anglogenesis and the destruction of new angiogenic vasculature. The present invention also features new compounds useful for imaging arteriosclerosis, restenosis, cardiac ischemia and myocardial perfusion injuries. The present invention also features new compounds useful for the treatment of rheumatoid arthritis. Pharmaceutical compositions comprise a targeted portion that binds to a receptor that is upwardly regulated during angiogenesis, an optional binding group, and a therapeutically effective radioisotope or a portion that can form a diagonally effective image. The imaging portion is a gamma ray or a positron-emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or a para-ultrasound contrast agent.